| Methods |
4‐week single‐blind placebo phase; inclusion criteria= sitting DBP 95‐115 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
All patients: 122(83 males,39 females); mean age=53(11) years; baseline BP for all randomized patients not reported;
Losartan 50 mg once daily: n=29;
Losartan 100 mg once daily: n=30;
Losartan 50 mg twice daily: n=31;
Placebo: n=32 |
| Interventions |
Losartan 50 mg once daily;
Losartan 100 mg once daily;
Losartan 50 mg twice daily;
Placebo;
administered between 7:30 AM and 10 AM and in the evening 12 h later |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD reported; SBP data from Figure 2, p. S32, DBP data from Figure 3, p. S33; Jadad score=4; funding source= Merck |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
